Peer-reviewed veterinary case report
Survival after surgery for dog mammary cancer with or without chemo
By Tran, C M et al.·Published in Veterinary and comparative oncology·2016·Animal Referral Hospital, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy.
- Species:
- dog
Plain-English summary
A group of dogs with mammary tumors underwent surgery to remove the cancer, with some also receiving chemotherapy afterward. The study found that dogs with complete surgical margins (meaning all cancer was removed) had a much better chance of living longer compared to those with incomplete margins. For dogs with advanced cancer, adding chemotherapy didn't significantly improve survival times. However, a few dogs with complete margins that received specific chemotherapy drugs lived significantly longer, averaging over three years.
People also search for: dog mammary tumor surgery · dog cancer survival rates · chemotherapy for dog mammary carcinoma
Abstract
This retrospective study identified prognostic factors associated with survival; and compared survival data in 94 canine mammary carcinoma (MCA) dogs treated with surgery (n = 58), or surgery and adjunct chemotherapy (n = 36), and a subset of dogs with poor prognostic factors. On multivariate analysis independent predictors of median survival time (MST) were clinical stage, lymphatic invasion (LI; present 179 days; none 1098 days), ulceration (present 118 days; none 443 days) and surgical margins (incomplete 70 days; complete 872 days). Complete surgical margins were associated with MST in dogs with stages 1-3 MCA (incomplete 68 days; complete 1098 days) and dogs with LI (incomplete 70 days; complete 347 days). There was no statistically significant improvement in MST in dogs with advanced disease (stage 4 or LI) treated with adjunctive chemotherapy (chemotherapy 228 days; none 194 days); although five dogs with complete surgical margins that received mitoxantrone and carboplatin had a mean survival of 1139 days.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24735412/